VANGUARD DEVELOPED MARKETS INDEX FUND
VANGUARD TAX-MANAGED FUNDS · Series S000004386 · 5 share classes
data updated 2026-08-10
Fund profile
As filed in the prospectus · 2026 Q2
Vanguard Developed Markets Index Fund (the Fund) seeks to track the performance of a benchmark index that measures the investment return of stocks issued by companies located in Canada and the major markets of Europe and the Pacific region.
The fund tracks the FTSE Developed All Cap ex US Index through full replication, holding all or substantially all of the index constituents in their market-weight proportions to match the performance of large-, mid-, and small-cap stocks in Canada, Europe, and the Pacific region.
| Share class | Expense ratio |
|---|---|
| VTMGX | 0.05% |
| VTMNX | 0.03% |
| VEA | 0.03% |
| VDIPX | 0.02% |
| VDVIX | 0.16% |
Portfolio turnover 4.00% · as of 2026 Q2
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q1
| Stocks | 99.09% |
| Cash & short-term | 1.25% |
| Derivatives | -0.01% |
The outer band is exposure held short — written against the portfolio rather than part of it, which is why it sits outside the ring and why the two are never netted into one figure.
Derivatives are shown at market value, not notional exposure.
Latest quarter
What changed since the fund's previous filing
Largest new: Roche Holding AG, Reckitt Benckiser Group PLC, SUNB, QIAGEN NV, Air Liquide SA, Abivax SA, Zijin Gold International Co Ltd, L'Oreal SA
Largest exited: Roche Holding AG, Reckitt Benckiser Group PLC, Ashtead Group PLC, Toyota Industries Corp, Hang Seng Bank Ltd, QIAGEN NV, New Gold Inc, Air Liquide SA
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Feb 2026
| Share class | 1-year | 3-year | 5-year | Vol | Worst fall |
|---|---|---|---|---|---|
| — | — | — | — | — | |
| — | — | — | — | — | |
| — | — | — | — | — | |
| — | — | — | — | — | |
| — | — | — | — | — |
Mar 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Value | Shares |
|---|---|---|---|---|
| SSNLF | Samsung Electronics Co LtdSSNLF | 1.89% | $5.32B | 45.5M |
| ASMLF | ASML Holding NVASMLF | 1.77% | $4.99B | 3.8M |
| — | Vanguard Cmt Funds-Vanguard Market Liquidity Fund | 1.25% | $3.53B | — |
| — | SK hynix Inc | 1.05% | $2.97B | 5.2M |
| NVSEF | Novartis AGNVSEF | 1.01% | $2.85B | 18.6M |
| — | AstraZeneca PLC | 1.00% | $2.84B | 14.5M |
| — | HSBC Holdings PLC | 0.97% | $2.73B | 166.2M |
| — | Roche Holding AG | 0.96% | $2.72B | 6.8M |
| — | Shell PLC | 0.90% | $2.55B | 55.1M |
| NSRGF | Nestle SANSRGF | 0.87% | $2.44B | 24.9M |
Top 10 positions are 11.67% of net assets, top 25 20.56%, across 3.8K issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free